Sign In
Buy BLU
$14.74
+0 (+0%)
At Close: Sep 27, 2023
Merck's (MRK) Pneumococcal Vaccine sBLA Faces FDA Delay
02:40pm, Monday, 04'th Apr 2022 Zacks Investment Research
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Can Bellus (BLU) Climb 70% to Reach the Level Wall Street Analysts Expect?
02:00pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 70.5% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive
Can Bellus (BLU) Climb 88% to Reach the Level Wall Street Analysts Expect?
03:00pm, Thursday, 24'th Feb 2022 Zacks Investment Research
The consensus price target hints at an 87.5% upside potential for Bellus (BLU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Can Bellus (BLU) Climb 88% to Reach the Level Wall Street Analysts Expect?
11:35am, Thursday, 24'th Feb 2022
The consensus price target hints at an 87.5% upside potential for Bellus (BLU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates
02:00am, Thursday, 24'th Feb 2022 Zacks Investment Research
Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bellus Health (BLU) Reports Q4 Loss, Lags Revenue Estimates
10:14pm, Wednesday, 23'rd Feb 2022
Bellus (BLU) delivered earnings and revenue surprises of 35.71% and 60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Bellus (BLU) Rating Upgrade to Buy
05:00pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Bellus (BLU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 65% Upside in Bellus (BLU): Here's What You Should Know
11:30am, Tuesday, 08'th Feb 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 65% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive t
Merck Coughs Up a Failure With Its "Pipeline in a Product"
12:03pm, Thursday, 03'rd Feb 2022 The Motley Fool
The FDA rejected Merck's filing for approval of gefapixant in treating chronic cough.
Merck's (MRK) Chronic Cough Drug Gets CRL From FDA
04:13pm, Tuesday, 25'th Jan 2022 Zacks Investment Research
Merck's (MRK) new drug application for gefapixant to treat refractory chronic cough or unexplained chronic cough fails to secure approval from the FDA. Meanwhile, the drug secures approval in Japan.
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
02:25am, Wednesday, 15'th Dec 2021 Kwhen Finance
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
10:19pm, Tuesday, 14'th Dec 2021 Zacks Investment Research
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
Bellus (BLU) Stock Surges on Data From Chronic Cough Study
06:23pm, Tuesday, 14'th Dec 2021
Bellus Health (BLU) achieves the primary endpoint in a phase IIb study evaluating BLU-5937 for the treatment of refractory chronic cough.
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
01:22pm, Tuesday, 14'th Dec 2021 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Vaccitech To Buy Avidea For $40M
Vaccitech plc (NASDAQ: VACC) announced that it has acquired U.S.-base
BELLUS Proof Of Data In Chronic Cough Using BLU-5937 Brings Hope To Patients
05:22am, Tuesday, 14'th Dec 2021
BELLUS achieved primary endpoint of phase 2b SOOTHE study using BLU-5937 in patients with refractory chronic cough. An end of phase 2b meeting with the FDA for BLU-5937 in refractory chronic cough is
